PCVX Price Prediction Next Week
Technical Analysis Based on recent price action, PCVX is showing mixed signals. The stock is currently trading at $87.42, slightly below its 200-day SMA of $87.84. The RSI-14 reading of 49.28 indicates neutral momentum, neither overbought nor oversold. The MACD shows a slight positive divergence at 0.27, suggesting potential upward momentum.
News and Institutional Analysis Recent insider selling activity, with COO Jim Wassil selling 2,666 shares, and 120 insider sales with no purchases in the past 6 months could signal some caution. However, institutional sentiment remains mixed but relatively positive, with 203 institutions increasing positions versus 117 decreasing.
Price Targets and Projections Analyst consensus shows an average target price of $146.56, suggesting a significant 65.28% upside potential from current levels.
Next Week's Price Projection Based on Fibonacci levels and technical indicators:
- Support levels: $84.87 (S1), $82.46 (S2)
- Resistance levels: $92.64 (R1), $95.05 (R2)
Price Prediction: PCVX is expected to trade between $84.87-$92.64 next week, with a target price of $90.50.
Recommendation: BUY with entry point at current levels ($87.42) or on dips near $84.87. Set stop loss at $82.46.
Rationale:
- Strong analyst price targets
- Positive institutional buying trend
- Technical support at Fibonacci levels
- Positive MACD divergence
PCVX Similar Chart Price Prediction
The price of PCVX is predicted to go up 10.11%, based on the high correlation periods with MPX. The similarity of these two price pattern on the periods is 90.14%.
PCVX
MPX
Up: 10.11%Similarity: 90.14%
PCVX Revenue Forecast
PCVX EPS Forecast
PCVX FAQs
What is bull’s view on PCVX?
What is bear's view on PCVX?
PCVX Analyst's Forecast
Chris Shibutani
Goldman Sachs
Strong Buy
2024-12-20
Price Target
$135
Upside
+56.02%
Goldman Sachs analyst Chris Shibutani initiated coverage of Vaxcyte with a Buy rating and $135 price target. The firm says clinical data for the company's lead programs provide a "foundation for viewing" its core longer-term fundamentals as "strongly positive." The recent relative underperformance of the shares, driven primarily by uncertainties deriving from broader macro and healthcare policy-related uncertainties, creates an "especially attractive entry point," the analyst tells investors in a research note. Goldman believes Vaxcyte's upcoming data in Q1 for VAX-24 in the infant and pediatric population "provides a potentially high impact near-term catalyst."
